Search | Clinical Trials Finder

Conditions: Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions: 40 mg MSB11022; Drug
Lead sponsor: Fresenius Kabi SwissBioSim GmbH; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Tinea Corporis
Interventions: Naftin Cream, Placebo Cream; Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Tucson, Arizona • Encino, California • Fremont, California + 10 more

Conditions: HCV Infection
Interventions: EBR/GZR FDC Tablet, Placebo, Grazoprevir Oral Granules, Elbasvir Oral Granules; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: San Francisco, California • Orlando, Florida • Atlanta, Georgia + 5 more

Conditions: Asthma, Smoking Cessation
Interventions: Cessation Counseling; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Day and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Congenital Heart Disease, Sepsis, Infection
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: Up to 5 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: RSV Infections
Interventions: Not listed
Lead sponsor: Shionogi; Industry
Eligibility: Up to 36 Months
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Syracuse, New York • Seattle, Washington

Conditions: SARS-CoV Infection, Covid19
Interventions: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination); Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 12 Years and older
Enrollment: 33,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 144
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Emtricitabine, Stavudine; Drug
Lead sponsor: Triangle Pharmaceuticals; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more

Conditions: Urinary Tract Infections
Interventions: Gepotidacin, SOC; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Orange, California • Shreveport, Louisiana • Baltimore, Maryland + 1 more

Conditions: Adenovirus Infections
Interventions: cidofovir, Brincidofovir; Drug
Lead sponsor: SymBio Pharmaceuticals; Industry
Eligibility: 2 Months and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 32
States / cities: Phoenix, Arizona • Duarte, California • Palo Alto, California + 25 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir Pediatric Granules, Dolutegravir Dispersible Tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Congenital Disorders
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Up to 18 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 10 Months to 25 Years
Enrollment: 1,993 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Community-acquired Pneumonia, Skin Infection
Interventions: Education and feedback, Clinical decision support; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV-1
Interventions: Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: Syracuse, New York • Memphis, Tennessee

Conditions: Lyme Disease, Pediatric Infectious Disease, Erythema Migrans, Lyme Arthritis, Lyme Carditis, Lyme Disease Meningitis
Interventions: Not listed
Lead sponsor: Stony Brook University; Other
Eligibility: 1 Year to 17 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Setauket, New York

Conditions: Microbial Colonization
Interventions: Prebiotics, Placebos; Dietary Supplement
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 2 Years to 18 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV/AIDS
Interventions: REMUNE; Biological
Lead sponsor: Immune Response BioPharma, Inc.; Industry
Eligibility: 3 Months to 16 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions: Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 29
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more

Conditions: Crohn's Disease, Inflammatory Bowel Disease
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Months to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Recurrent Urinary Tract Infection
Interventions: Lactobacillus reuteri DSM 17938, trimethoprim/sulfamethoxazole; Dietary Supplement · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Months to 17 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C), Coronavirus Disease 2019 (COVID-19)
Interventions: SARS-CoV-2 and/or MIS-C Exposure; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 20 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 20
States / cities: Loma Linda, California • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Pediculosis
Interventions: Malathion gel 0.5%, Permethrin 1% rinse (Nix Crème); Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Hot Springs, Arkansas • Sacramento, California • Kissimmee, Florida + 4 more

Conditions: Herpes Simplex
Interventions: Famciclovir; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 12 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 11
States / cities: Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 8 more

Search by objective public record fields.

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

Pediatric Subjects With Tinea Corporis

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke

Pro-Calcitonin Levels Following Pediatric Cardiac Surgery

A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric Participants

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

Chlorhexidine Swabs Effectiveness in Reducing Blood Stream Infections

Quality of Life in Children With HIV Infection

Improving Short Course Treatment for Common Pediatric Infections

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

Next Generation Sequencing Detection of Lyme Disease

The Use of A Prebiotic to Promote a Healthy Gut Microbiome in Pediatric Stem Cell Transplant Recipients

REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Infectious Agents in Pediatric Crohn's

Probiotics for Girls With Recurring Urinary Tract Infections

COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection